Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cingulate Inc ( (CING) ) just unveiled an announcement.
Between July 22, 2025, and September 5, 2025, Cingulate Inc. issued several tranches of common stock to a lender in exchange for portions of debt owed, with each issuance being exempt from registration under the Securities Act of 1933. These transactions, involving a total of 325,729 shares, were executed at varying per-share values, reflecting strategic financial maneuvers to manage the company’s debt obligations.
The most recent analyst rating on (CING) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Cingulate Inc stock, see the CING Stock Forecast page.
Spark’s Take on CING Stock
According to Spark, TipRanks’ AI Analyst, CING is a Neutral.
Cingulate Inc.’s overall stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. However, recent corporate developments, such as securing a grant and progress towards FDA approval, provide a positive outlook. The technical analysis shows neutral momentum, but valuation remains a concern due to financial losses and lack of dividends.
To see Spark’s full report on CING stock, click here.
More about Cingulate Inc
Average Trading Volume: 133,015
Technical Sentiment Signal: Sell
Current Market Cap: $20.51M
See more insights into CING stock on TipRanks’ Stock Analysis page.